The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

The Intrathecal Drug Administration System

척수강 내 약물 주입술

  • Nahm, Francis Sahngun (Department of Anesthesiology and Pain Medicine, Seoul National University School of Medicine) ;
  • Kim, Yong Chul (Department of Anesthesiology and Pain Medicine, Seoul National University School of Medicine)
  • 남상건 (서울대학교 의과대학 마취통증의학교실) ;
  • 김용철 (서울대학교 의과대학 마취통증의학교실)
  • Received : 2009.07.29
  • Accepted : 2009.07.31
  • Published : 2009.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

The intrathecal drug administration system (ITDAS) has recently been introduced for treating chronic intractable pain patients who have failed with conservative pain treatments. The obvious advantages of its use are the direct intrathecal delivery of drugs, which yields reduced adverse effects and the increased strength of drugs, as compared to its oral or intravenous route. This article offers a review of the ITDAS with a brief review of its evidence-based effectiveness, the technical approach, and the complications.

Keywords

References

  1. Expert Working Group of the European Association for Palliative Care: Morphine in cancer pain: modes of administration. BMJ 1996; 312: 823-6 https://doi.org/10.1136/bmj.312.7034.823
  2. Sylvester RK, Lindsay SM, Schauer C: The conversion challenge: from intrathecal to oral morphine. Am J Hosp Palliat Care 2004; 21: 143-7 https://doi.org/10.1177/104990910402100214
  3. Yaksh TL, Rudy TA: Narcotic analgestics: CNS sites and mechanisms of action as revealed by intracerebral injection techniques. Pain 1978; 4: 299-359 https://doi.org/10.1016/0304-3959(77)90145-2
  4. Lee SJ, Nam SK, Kim JH, Kim HJ, Lee SC, Kim YC: Implantation of an intrathecal drug administration system: a report of two cases. Korean J Pain 2009; 22: 68-73 https://doi.org/10.3344/kjp.2009.22.1.68
  5. Seo KS, Han KR, Kim SY, Park KE, Kim C: Implantable Intrathecal drug delivery pump in complex regional pain syndrome patient: a case report. Korean J Pain 2009; 22: 74-7 https://doi.org/10.3344/kjp.2009.22.1.74
  6. Yaksh TL, Rudy TA: Analgesia mediated by a direct spinal action of narcotics. Science 1976; 192: 1357-8 https://doi.org/10.1126/science.1273597
  7. Wang JK, Nauss LA, Thomas JE: Pain relief by intrathecally applied morphine in man. Anesthesiology 1979; 50: 149-51 https://doi.org/10.1097/00000542-197902000-00013
  8. Onofrio BM, Yaksh TL, Arnold PG: Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc 1981; 56: 516- 20
  9. Leavens ME, Hill CS Jr, Cech DA, Weyland JB, Weston JS: Intrathecal and intraventricular morphine for pain in cancer patients: initial study. J Neurosurg 1982; 56: 241-5 https://doi.org/10.3171/jns.1982.56.2.0241
  10. Rico RC, Hobika GH, Avellanosa AM, Trudnowski RJ, Rempel J, West CR: Use of intrathecal and epidural morphine for pain relief in patients with malignant diseases: a preliminary report. J Med 1982; 13: 223-31
  11. Auld AW, Maki-Jokela A, Murdoch DM: Intraspinal narcotic analgesia in the treatment of chronic pain. Spine 1985;10: 777-81 https://doi.org/10.1097/00007632-198510000-00014
  12. Paice JA, Penn RD, Shott S: Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage 1996; 11: 71-80 https://doi.org/10.1016/0885-3924(95)00099-2
  13. Brazenor GA: Long term intrathecal administration of morphine: a comparison of bolus injection via reservoir with continuous infusion by implanted pump. Neurosurgery 1987; 21: 484-91 https://doi.org/10.1227/00006123-198710000-00008
  14. Johnston J, Reich S, Bailey A, Sluetz J: Shiley INFUSAID Pump technology. Ann N Y Acad Sci 1988; 531: 57-65 https://doi.org/10.1111/j.1749-6632.1988.tb31812.x
  15. Belverud S, Mogilner A, Schulder M: Intrathecal pumps. Neurotherapeutics 2008; 5: 114-22 https://doi.org/10.1016/j.nurt.2007.10.070
  16. Smith HS, Deer TR, Staats PS, Singh V, Sehgal N, Cordner H: Intrathecal drug delivery. Pain Physician 2008; 11(Suppl): 89-104
  17. Patel VB, Manchikanti L, Singh V, Schultz DM, Hayek SM, Smith HS: Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain. Pain Physician 2009; 12: 345-60
  18. Anderson VC, Burchiel KJ: A prospective study of longterm intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 1999; 44: 289-300 https://doi.org/10.1097/00006123-199902000-00026
  19. Angel IF, Gould HJ Jr, Carey ME: Intrathecal morphine pump as a treatment option in chronic pain of nonmalignant origin. Surg Neurol 1998; 49: 92-8 https://doi.org/10.1016/S0090-3019(97)00287-5
  20. Hassenbusch SJ, Stanton-Hicks M, Covington EC, Walsh JG, Guthrey DS: Long-term intraspinal infusions of opioids in the treatment of neuropathic pain. J Pain Symptom Manage 1995; 10: 527-43 https://doi.org/10.1016/0885-3924(95)00087-F
  21. Winkelm$\ddot{u}$ller M, Winkelm$\ddot{u}$ller W: Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg 1996; 85: 458-67 https://doi.org/10.3171/jns.1996.85.3.0458
  22. Roberts LJ, Finch PM, Goucke CR, Price LM: Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain 2001; 5: 353-61 https://doi.org/10.1053/eujp.2001.0255
  23. Thimineur MA, Kravitz E, Vodapally MS: Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study. Pain 2004; 109: 242-9 https://doi.org/10.1016/j.pain.2004.01.003
  24. Rauck RL, Cherry D, Boyer MF, Kosek P, Dunn J, Alo K: Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain 2003; 4: 441-7 https://doi.org/10.1067/S1526-5900(03)00730-2
  25. Smith TJ, Coyne PJ, Staats PS, Deer T, Stearns LJ, Rauck RL, et al: An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol 2005; 16: 825-33 https://doi.org/10.1093/annonc/mdi156
  26. Anderson VC, Cooke B, Burchiel KJ: Intrathecal hydromorphone for chronic nonmalignant pain: a retrospective study. Pain Med 2001; 2: 287-97 https://doi.org/10.1046/j.1526-4637.2001.01052.x
  27. Doggrell SA: Intrathecal ziconotide for refractory pain. Expert Opin Investig Drugs 2004; 13: 875-7 https://doi.org/10.1517/13543784.13.7.875
  28. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004; 291: 63-70 https://doi.org/10.1001/jama.291.1.63
  29. Van Dongen RT, Crul BJ, van Egmond J: Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 1999; 15: 166-72 https://doi.org/10.1097/00002508-199909000-00002
  30. Deer TR, Caraway DL, Kim CK, Dempsey CD, Stewart CD, McNeil KF: Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J 2002; 2: 274-8 https://doi.org/10.1016/S1529-9430(02)00199-7
  31. Classen AM, Wimbish GH, Kupiec TC: Stability of admixture containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system. J Pain Symptom Manage 2004; 28: 603-11 https://doi.org/10.1016/j.jpainsymman.2004.04.011
  32. Raphael JH, Southall JL, Gnanadurai TV, Treharne GJ, Kitas GD: Long-term experience with implanted intrathecal drug administration systems for failed back syndrome and chronic mechanical low back pain. BMC Musculoskelet Disord 2002; 3: 17 https://doi.org/10.1186/1471-2474-3-17
  33. Nordberg G, Hedner T, Mellstrand T, Dahlströom B: Pharmacokinetic aspects of intrathecal morphine analgesia. Anesthesiology 1984; 60: 448-54 https://doi.org/10.1097/00000542-198405000-00010
  34. Moore A, Bullingham R, McQuay H, Allen M, Baldwin D, Cole A: Spinal fluid kinetics of morphine and heroin. Clin Pharmacol Ther 1984; 35: 40-5 https://doi.org/10.1038/clpt.1984.6
  35. Payne R, Inturrisi CE: CSF distribution of morphine, methadone and sucrose after intrathecal injection. Life Sci 1985; 37: 1137-44 https://doi.org/10.1016/0024-3205(85)90357-1
  36. Faura CC, Collins SL, Moore RA, McQuay HJ: Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain 1998; 74: 43-53 https://doi.org/10.1016/S0304-3959(97)00142-5
  37. Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE: Morphine- 6-glucuronide, a potent mu agonist. Life Sci 1987; 41: 2845-9 https://doi.org/10.1016/0024-3205(87)90431-0
  38. Hassenbusch SJ, Paice JA, Patt RB, Bedder MD, Bell GK: Clinical realities and economic considerations: economics of intrathecal therapy. J Pain Symptom Manage 1997; 14(3 Suppl): 36-48 https://doi.org/10.1016/S0885-3924(97)00169-3
  39. Hassenbusch SJ: Cost modeling for alternate routes of administration of opioids for cancer pain. Oncology (Williston Park) 1999; 13(5 Suppl 2): 63-7
  40. Koulousakis A, Kuchta J, Bayarassou A, Sturm V: Intrathecal opioids for intractable pain syndromes. Acta Neurochir Suppl 2007; 97(Pt 1): 43-8
  41. Kumar K, Kelly M, Pirlot T: Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. Surg Neurol 2001; 55: 79-86 https://doi.org/10.1016/S0090-3019(01)00353-6
  42. Medtronic Inc: Medtronic Synchromed II programmable infusion system clinical reference guide: pain management. 2004
  43. Krames ES, Olson K: Clinical realities and economic considerations: patient selection in intrathecal therapy. J Pain Symptom Manage 1997; 14(3 Suppl): 3-13 https://doi.org/10.1016/S0885-3924(97)00166-8
  44. France JC, Jorgenson SS, Lowe TG, Dwyer AP: The use of intrathecal morphine for analgesia after posterolateral lumbar fusion: a prospective, double-blind, randomized study. Spine 1997; 22: 2272-7 https://doi.org/10.1097/00007632-199710010-00015
  45. Krames ES: Intrathecal infusional therapies for intractable pain: patient management guidelines. J Pain Symptom Manage 1993; 8: 36-46 https://doi.org/10.1016/0885-3924(93)90118-F
  46. Yaksh TL, Onofrio BM: Retrospective consideration of the doses of morphine given intrathecally by chronic infusion in 163 patients by 19 physicians. Pain 1987; 31: 211-23 https://doi.org/10.1016/0304-3959(87)90037-6
  47. Ruan X: Drug-related side effects of long-term intrathecal morphine therapy, Pain Physician 2007; 10: 357-66
  48. Miele VJ, Price KO, Bloomfield S, Hogg J, Bailes JE: A review of intrathecal morphine therapy related granulomas. Eur J Pain 2006; 10: 251-61 https://doi.org/10.1016/j.ejpain.2005.05.002
  49. Singh PK, Jain R, Mishra S, Kumar S, Bhatnagar S, Deo S: Management of pericatheter cerebrospinal fluid leak after intrathecal implantation of a drug delivery system. Am J Hosp Palliat Care 2008; 25: 237-9 https://doi.org/10.1177/1049909108315520
  50. Medtronic Inc: Medtronic Synchromed II programmable infusion system clinical reference guide: surgical procedures. 2004

Cited by

  1. An Improved Method for Intrathecal Catheterization in the Rat vol.26, pp.4, 2010, https://doi.org/10.5625/lar.2010.26.4.393
  2. Catheter Obstruction of Intrathecal Drug Administration System -A Case Report- vol.25, pp.1, 2012, https://doi.org/10.3344/kjp.2012.25.1.47